Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.

Department of Pathology, Odense University Hospital, Winsløwparken 15, DK-5000 Odense C, Denmark.
British Journal of Haematology (Impact Factor: 4.94). 02/2004; 124(2):151-9. DOI: 10.1046/j.1365-2141.2003.04749.x
Source: PubMed

ABSTRACT Differences in genetic origin between nodal and extranodal diffuse large B-cell lymphomas (DLBCL) exist. Using population-based data from the registry of the Danish Lymphoma Group, the present study is the first to analyse clinical implications of nodal versus extranodal presentation of DLBCL. Of 4786 newly diagnosed non-Hodgkin's lymphoma patients in a 16-year period, 1575 (33%) had DLBCL. The annual incidence rate was 2.9 per 100 000; 40% were extranodal. The clinical profile of patients with extranodal DLBCL was different from the nodal DLBCL patients. Extranodal DLBCL was associated with older age and poorer performance score, but also lower tumour burden. In extranodal DLBCL, 51% of the cases were stage I and 36% were stage IV, whereas the patients were relatively equally distributed between the four stages in nodal DLBCL. For stage I patients, extranodal DLBCL was independently associated with poor survival (P = 0.003). In contrast, among stage IV patients those with extranodal DLBCL survived longer (P = 0.009). We conclude that there are important clinical differences between nodal and extranodal DLBCL. The addition of these clinical results to the existing aetiological and genetic data suggests that the distinction between nodal and extranodal DLBCL is not only pathogenetically but also clinically important.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Diffuse large B-cell lymphoma is the most common lymphoid neoplasm, accounting for approximately 25% of all non-Hodgkin lymphomas. Patients typically present with nodal enlargement, fever, weight loss, or night sweats. Extranodal extramedullary disease occurs in up to 40% of cases with the most common site of extranodal involvement being the gastrointestinal tract. However, diffuse large B-cell lymphoma can present in virtually any area, including the testes, bones, thyroid, salivary glands, tonsils, skin, liver, breasts, adrenals, kidneys, nasal cavity, paranasal sinuses, cervix, and central nervous system.
    Ochsner Journal 01/2014; 14(2):248-51.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Using the Surveillance, Epidemiology, and End Results (SEER)–Medicare database, we investigated the relative benefits of adding rituximab to CHOP chemotherapy in diffuse large B-cell lymphoma (DLBCL) of extranodal origin, and found similar advantage for nodal and extranodal lymphomas. Hazard ratio for overall survival was 0.64 for nodal, and 0.70 for extranodal DLBCL. Hazard ratios for lymphoma-related death were 0.62 and 0.57, respectively. The advantage was largest for DLBCL of the spleen, liver and lung. Conversely, it was not evident for thyroid or testicular lymphomas. Compared with nodal DLBCL, spleen was the only site with significantly better prognosis after R-CHOP.
    Leukemia research 05/2014; · 2.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diffuse Large B-Cell Lymphomas (DLBCL) correspond to 50% of non-Hodgkin's lymphomas. Since 1993 the treatment of these patients has been directed by the International Prognostic Index (IPI), validated in several studies. However, the use of the IPI has not been evaluated in our population and social-economical conditions. In this study, we evaluate the impact of the age-adapted IPI (aIPI) in the complete response, overall survival and disease-free survival in under 60-year-old DLBCL sufferers treated in the Hematology Service of HCFMUSP. Of the 111 evaluated patients, 60 were classified as aIPI low and intermediate risk and 51 as aIPI intermediate-high and high risk. The patients with low and intermediate risk were analyzed as a whole with adapted low risk and patients with intermediate-high and high risk with the adapted high risk. We verified that the overall survival and disease-free survival were influenced by the clinic stage, LDH value and patients performance status. We recommend the regular use of IPI in the treatment of the patients with DLBCL in our institution.
    Revista Brasileira de Hematologia e Hemoterapia 03/2005; 27(1):27-30.


1 Download